Project description DEENESFRITPL AI helps a non-invasive ICU device keep blood glucose levels healthy in real time Glucose is the main source of energy for all the metabolic processes of our cells. Keeping a proper balance is critical to everything from brain function to wound healing to muscle contraction. Over the last couple decades, it has become increasingly clear that improper glucose homeostasis in ICU patients is associated with significant morbidity and mortality. Continuous glucose monitoring can more efficiently detect hyper- and hypoglycaemia before harm is done compared to sporadic testing and offline analysis. The EU-funded ContiTRACE project is laying the groundwork to take its non-invasive continuous glucose monitoring and automatic insulin infusion device to market. The ContiTRACE device promises to significantly reduce caretaker workloads and healthcare system costs while improving the outcomes of ICU patients. Show the project objective Hide the project objective Objective Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15+ years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinecritical care medicinesocial scienceseconomics and businessbusiness and managementbusiness modelsengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TRACE ANALYTICS GMBH Net EU contribution € 50 000,00 Address RICHARD WAGNER STRASSE 1-2 38106 BRAUNSCHWEIG Germany See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
